Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsGraft SurvivalPeripheral Blood Stem Cell TransplantationBusulfanTreatment OutcomeLeukemiaHistocompatibilityHistocompatibility TestingRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticStem CellsMyelodysplastic SyndromesImmunosuppressive AgentsVidarabineRemission InductionCord Blood Stem Cell TransplantationLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLiver TransplantationTransplantation, IsogeneicLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapySiblingsTime FactorsTransplantation ImmunologySurvival RateSurvival AnalysisHematopoiesisCytomegalovirus InfectionsAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesDisease-Free SurvivalSevere Combined ImmunodeficiencyMice, Inbred C57BLFollow-Up StudiesOpportunistic InfectionsMultiple MyelomaCystitisFlow CytometryKidney TransplantationMinor Histocompatibility AntigensLeukemic InfiltrationImmunosuppressionHematopoietic Stem Cell MobilizationLeukemia, MyeloidAntigens, CD34Antilymphocyte SerumNeoplasm, ResidualSalvage TherapyLymphoproliferative DisordersBone and BonesGraft RejectionCell DifferentiationAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusPrognosisImmunocompromised HostRisk FactorsBlood Group IncompatibilityFatal OutcomeBronchiolitis ObliteransCyclosporineBone Marrow PurgingCytarabineCell TransplantationColony-Forming Units AssayMelphalanMesenchymal Stem Cell TransplantationMycosesPrimary MyelofibrosisHeart TransplantationLymphoma, Non-HodgkinRadiation ChimeraCell LineageGanciclovir